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 Autoimmune disease is characterized by aberrant immunological 
activation. Heat shock protein beta 1 (HSPB1) or gp 96, HSP90 family member, is 
an endoplasmic reticulum (ER)-resident chaperone protein. It is involved in 
immunological activity and its cell surface localization induces autoimmune 
disease. In autoimmune disease, HSPB1 no longer retrogrades from golgi to the ER 
but translocates to cell surface instead. Cell surface expressed HSPB1 induces 
abnormal activation of dendritic cells (DCs) and DCs activate immune cells. 
Aberrantly activated immune cells attack normal tissues and consequently induce 
autoimmune disease. Aminoacyl-tRNA synthetase-interacting multifunctional 
protein 1 (AIMP1), found in multi-tRNA synthetase complex (MSC), supports 
HSPB1 in retrograde transport from golgi to the ER. In autoimmune disease, the 
interaction between HSPB1 and AIMP1 is disassociated, leading to translocation of 
HSPB1 to the cell surface. Therefore, the role of AIMP1 is essential in regulation 
of HSPB1 cell surface level and thereby in autoimmune disease.  
Previously, chemical named GPM1 was introduced to control cell surface 
translocation of HSPB1 by substituting for the role of AIMP1 and to alleviate the 
autoimmune disease-associated symptoms in vivo. However, GPM1 had poor 
metabolic stability to be developed as a therapeutic drug. Metabolic 
biotransformation of a drug can alter the half-life of the drug and determine the 
drug response to the agent. Screening metabolic stability in the early stages of drug 
development is a critical step in drug discovery that it has significant effect on 




'chemical KR-S-026S' dramatically reduced cell surface localization of HSPB1 and 
strikingly ameliorated autoimmune phenotype in vivo. KR-S-026S had enhanced 
effect and also had higher metabolic stability compared to GPM1. These results 
suggest that chemical KR-S-026S is a promising compound to alleviate 
autoimmune disease by substituting for the role of AIMP1 and support HSPB1 to 
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 Autoimmune disease is characterized by autoantibody production and 
immune complex stimulation (1). The mechanism that elicits this phenotype is 
aberrant activation of immune cells by abnormally matured dendritic cells (DCs); 
and those immune cells attack normal tissues, progressing to irreversible organ 
damage and consequently increasing the risk of premature death (2). At the 
interface of innate and adaptive immunity, DCs play crucial role in regulating 
immune responses. Matured DCs activate autoimmune T cells by presenting 
antigen for T cells; and T cells support the differentiation of autoreactive B cells, 
increasing the production of autoantibodies (3-5). The widespread deposition of 
immune complexes accumulates in the kidneys, leading to glomerulonephritis and 
renal failure (6). There are immunosuppressive therapy such as corticosteroids but 
have such side effects as infections, osteoporosis and atherogenesis (7).  
 Glycoprotein 96 (gp96) or HSP90B1, member of heat shock protein (HSP) 
90 family, is an endoplasmic reticulum (ER)-resident chaperone protein (8). 
Endoplasmic reticulum (ER) chaperones such as HSPB1, calreticulin, and 
isomerases recycle back to ER by retrograde transport from golgi through coatomer 
protein complex (COPI)-coated vesicles (9, 10). COPI is a protein complex that 
forms a coat around non-clathrin-coated vesicles to transport from the cis end of 
the golgi back to the rough ER (11). ER chaperones are equipped with C-terminal 
Lys-Asp-Glu-Leu (KDEL) motif which is recognized by the KDEL receptor, 
ERD2 (12, 13). Chaperones recognized by ERD2 induces oligomerization, leading 




chaperones can translocate to the cell surface under ER stress, and ER chaperones 
in the extracellular space can take on immunogenic characteristics (15). The 
association between autoimmune disease and HSPB1 has been studied that cell 
surface exposed HSPB1 directly interacts with and activates DCs via toll-like 
receptor (TLR) 2- and 4- signal transduction pathways (16). And abnormally 
matured DCs result in secretion of proinflammatory cytokines and upregulation of 
MHC class I and II molecules, consequently inducing autoimmune disease. In 
transgenic mouse that constitutively express cell surface HSPB1 induced by 
removing the C-terminal ER-retention signal KDEL of HSPB1, showed 
significantly increased level of activated DCs and spontaneously developed 
autoimmune disease phenotypes (17). Therefore, many studies understanding how 
these chaperone proteins translocate to the cell surface are in a process for the 
development of immune-based therapy. 
 Aminoacyl-tRNA synthetase (ARS)-interacting multi-functional protein 1 
(AIMP1) or p43, a component of the multisynthetase complex (MSC), is involved 
in diverse physiological activities. AIMP1 works as a pleiotropic cytokine on 
endothelial cells, fibroblasts, and monocytes to regulate angiogenesis, wound 
healing, and (18). Moreover, AIMP1 downregulates transforming growth factor 
beta (TGF-β) signaling by stabilizing smad ubiquitination regulatory factor 2 
(Smurf2), negative regulator of TGF-β signaling pathway (19). Furthermore, 
previous reports about AIMP1 in immune response elicited that AIMP1 can also 
regulate innate immune response by inducing maturation of DCs (20). AIMP1 is 




retention of HSPB1 and prevents extracellular translocation of HSPB1. The 
interaction between HSPB1 and KDEL receptor is enhanced by AIMP1, inducing 
dimerization of HSPB1 (21). AIMP1 has a crucial role in inhibition of extracellular 
translocation of HSPB1 and thereby in immunological implication. For instance, 
AIMP1-deficient mice developed autoimmune disease phenotypes that the mice 
had increased production of autoantibodies, high number of immune cells 
infiltrated through various organs, accumulated autoantibodies, and 
glomerularnephritis (18).  
 Previously, chemical named GPM1 was introduced to inhibit cell surface 
localization of HSPB1 by directly interacting with HSPB1. GPM1 binds at the 
vicinity of dimerization interface of HSPB1 and stabilizes HSPB1 dimer formation. 
GPM1 competes against AIMP1 to bind HSPB1 and functionally mimics AIMP1 
that GPM1 inhibits extracellular translocation of HSPB1 by assisting the 
interaction between HSPB1 and KDEL receptor. Furthermore, autoimmune disease 
phenotypes of HSPB1tm transgenic mice which had chronically enhanced HSPB1 
surface level, were ameliorated upon GPM1 treatment. Treatment of GPM1 in 
HSPB1tm transgenic mice decreased maturation of DCs, B cells and memory T 
cells, ameliorated glomerulonephritis phenotypes, and reduced autoantibodies level 
(22). In this study, we analyzed the chemical properties of GPM1 and observed that 
GPM1 had excessively low metabolic stability to become an ideal drug. Therefore, 
we synthesized GPM1 derivatives and suggest the most effective chemical with 





MATERIAL AND METHODS 
Cell culture and chemical treatment 
RAW 264.7 cells were purchased from Korean Cell Line Bank (KCLB) and were 
grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal 
bovine serum (FBS) and 1% penicillin at 37
o
C in 5% CO2. 
Madin-Darby Canine Kidney (MDCK) epithelial cells were obtained from the 
American Type Culture Collection (ATCC) and were grown in Minimal Essential 
Medium containing 10% FBS and 2 mM fresh L-glutamine at 37
o
C in 5% CO2. 
All GPM1 derivatives were synthesized by Syngene International Ltd Company. 
All chemicals were dissolved in dimethyl sulfoxide (DMSO).  
Western blot Analysis 
Whole cell protein extracts were isolated with cold lysis buffer (25 mM Tris-HCL 
pH 7.4, 150 mM NaCl, 10% glycerol, 2 mM ethylenediaminetetraacetic acid 
(EDTA), 1% Triton X-100, 0.1% SDS, and protease inhibitor) for 30 min at 4
o
C. 
After collected lysates were centrifuged at 13,200 rpm for 15 min at 4
o
C, 
supernatant proteins were quantified by Bradford assay (Biorad), followed by 
equalization of the sample concentration with sample buffer and lysis buffer.  
Samples were separated by SDS-PAGE and transferred to polyvinylidenefluoride 
(PVDF) membranes (Milipore) at 55 mA, 6 V for 1 h 30 min (BioRad). After the 
membranes were blocked with 5% skim milk in 0.5% TBS-T for 1 h, they were 




TBS-T overnight at 4
o
C. Membranes were washed 3 times with 0.5% TBS-T buffer 
for 7 min respectively and incubated with secondary antibody (Thermo Scientific) 
diluted in 1% skim milk in TBS-T for 1 h at room temperature. ECL solution 
(Santacruz biotechnology) was applied to the membrane according to the 
manufacturer's protocols.  
Antibodies were obtained from the following sources: rabbit polyclonal HSPB1 
antibody (Santacruz Biotechnology), anti-sodium potassium ATPase antibody 
(Abcam), α-tubulin antibody (Santacruz Biotechnology). 
Immunofluorescence 
Cells were seeded onto 9 x 9 mm cover slips (Bellco Glass Inc.) at 2.5 x 10
4
 
cells/well overnight and were treated with chemical compounds for 16 h. Cells 
were fixed with 4% paraformaldehyde (PFA, Biosesang) for 10 min at room 
temperature and blocked with CAS-block (Life Techonology) without 
permeabilization step being followed. After blocking step, cells were subjected to 
immunofluorescene staining with rabbit polyclonal HSPB1 (1:100) antibody 
(Santacruz Biotechnology) diluted in PBS with 10% CAS-block for 2 h at 4
o
C. 
Cells were incubated with FITC-conjugated anti-rabbit (1:200) secondary antibody 
(Invitrogen) diluted in PBS with 10% CAS-block for 1 h at 4
o
C. Then, cells were 
stained with DAPI (1 μg/ml, Sigma-Aldrich) for 5 min and mounted with 
mounting medium (Biomeda) on Micro Slides (Leica). Cells were examined by 






Cell surface level of HSPB1 was measured with Beckman Coulter flow cytometer. 
RAW 264.7 cells (1 x 10
6
 cells) were washed with cold PBS and were suspended in 
fluorescence-activated cell sorting (FACS) buffer (1% BSA in PBS). Cells were 
fixed with 2% PFA (Biosesang) diluted in PBS for 10 min and incubated with 1 μg 
of Fc blocker (BD Pharmingen) for 20 min at 4
o
C to block Fc receptors. After 
blocking non-specific bindings, cells were incubated with 0.8 μg of rabbit 
polyclonal HSPB1 antibody (Santacruz Biotechnology) for 1 h at 4
o
C and 
incubated with 1 μg of FITC-conjugated anti-rabbit secondary antibody (Invitrogen) 
for 20 min at 4
o
C. FACS data were analyzed with Navios software. 
Fractionation 
Cells were prepared in two 100 mm dishes at 2 x 10
6
 cells/dish. On the next day, 
cells were washed with cold-PBS and scraped into 1.5 ml tube. Cell pellet was 
collected by centrifuge at 1,000 rpm for 3 min at 4
o
C. After resuspending the pellet 
with buffer A (25 mM Tris-HCL pH 7.4, 1 mM EDTA, 0.5 mM EGTA, 10 mM 
NaCl), samples were homogenized 20-30 times. 1/10 volume of 2.5 M sucorse was 
added and centrifuged at 1,000 g for 10 min at 4
o
C. Supernatant was centrifuged at 
15,000 g for 15 min at 4
o
C and plasma membrane was isolated after resuspending 
the pellet with buffer B (25 mM Tris-HCl pH 7.4, 3 mM MgCl2, 10 mM NaCl, 0.25 
M sucrose). Additionally, Centrifuging the supernatant at 100,000 g for 1 h at 4
o
C 





Microsomal Stability Assay 
Compounds were diluted in DMSO to obtain 1 mM stock. Test compounds or 
controls were incubated for 5 min at 37
o
C after addition of 0.1 M phosphate buffer 
pH 7.4 and 10 mM NADPH. Human and rat liver microsomes (purchased from 
Sigma-Aldrich) were added for final concentration to be 0.5 mg/ml and incubated 
in a shaking water bath at 37
o
C. Samples were centrifuged at 10,000 g for 5 min at 
4
o
C and supernatants were collected. 
Standard curve was prepared by diluting 1 mM stock solution to 10, 1, and 0.1 μM 
in 0.1 M phosphate buffer. Percent stability (percent of remaining compound after 
metabolism) was analyzed with LC-MS/MS using Nexera XR system (Shimadzu) 
and TSQ vantage (Thermo) and stability was calculated as follows: 
Stability (%)  
                     
                 
 
Drug Permeability Assay 
The transepithelial electrical resistance (TEER) value, which represents the degree 
of development of monolayer confluence and tight junction, of MDCK cells was 
calculated. MDCK cells were washed with transport medium (Hanks' Balanced 
Salt Solution, HBSS, Gibco) and equilibrated in transport medium for 30 min at 
37
o
C. Using STX-2 chopstick electrode and volt-ohm meter (World Precision 
Instruments), electrical resistance of the cell was measured. TEER (Ω*cm
2
) value 
for each monolayer is the average of raw monolayer resistance value multiplied by 
the membrane area (0.33 cm
2




TEER values less than 90 Ω*cm
2
 (cutoff value for MDCK cells) were not used.  
The apparent permeability (Papp) level is determined by amount of chemical 
compound crossing apical (donor)-to-basolateral (acceptor) direction through cell 
monolayer (MDCK) cultured on 96-well polycarbonate membrane filters (Corning). 
Compounds were added at 50 μM with final DMSO concentration of 1% on the 
apical side solution (Gibco BRL) and incubated for 4 h at 25
o
C. Both Apical and 
basolateral solutions (Gibco BRL) were analyzed by LC-MS/MS and Papp value 
was calculated based on the amount of compound on the basolateral medium.  
Cell proliferation analysis using IncuCyteTM FLR 
Cells were plated in 96-well plate at 10,000 cells/well in triplicate. Chemicals were 
treated on the next day and photomicrographs were taken every 2 h using an 
IncuCyteTM FLR (Essen BioScience). The confluence of the cultures was 
monitored with IncuCyte Kinetic Live Cell Imaging System.  
Drug Administration 
NZB/W F1 female mouse with age of 20 weeks expressing autoimmune disease 
were obtained from Jackson laboratory. Chemicals were treated from the age of 24 
weeks for each experimental group. Groups were divided into three groups: vehicle 
group, GPM1 treated group and KR-S-026S treated group. GPM1 and KR-S-026S 
were treated at 30 mg/kg per injection. All chemicals were dissolved in 5% DMSO 






Urea from each groups of mouse were collected at the age of 23, 24, 26, 28, 30, 32 
weeks. Collected urines were centrifuged at 3000 rpm for 5 min and pellets were 




























Screening strategy to select the most effective compound targeting HSPB1 in 
cell surface translocation 
 In the previous study, we screened 6,482 chemical compounds that can 
directly interact with HSPB1 and decrease cell surface level of HSPB1 with no in 
vivo toxicity. Among those, GPM1 was selected for its ability to reduce cell surface 
level of HSPB1. It ameliorated the phenotypes of autoimmune disease in HSPB1tm 
transgenic mice in which cell surface HSPB1 level is chronically enhanced. 
However, GPM1 had poor chemical property to be further developed as a 
therapeutic drug (Fig 1A); therefore we synthesized GPM1 derivatives having 
similar chemical structure, 4,6-dimethoxy-pyrimidine (Fig 1B). We selected the 
most effective derivative in decreasing the cell surface HSPB1 level with enhanced 
chemical property.  
 KR-S-026S was selected by flow cytometry and GPM1 was used as a 
positive control that GPM1 reduced 40% of HSPB1 surface level (Fig 1C). 
Compounds KR-S-020, KR-S-022, KR-S-025S and KR-S-026S showed the most 
decreased cell surface HSPB1 level compared to other derivatives. KR-S-020, KR-
S-022, KR-S-025S and KR-S-026S reduced 56%, 57%, 59% and 63% of HSPB1 
surface level, respectively (Fig 1C). However, considering patentability, KR-S-020 
and KR-S-022 were omitted and KR-S-025S was also omitted due to its poor cell 
permeability level (data not shown). Therefore, KR-S-026S was selected as the 




Remarkable effect of KR-S-026S in regulating cell surface level of HSPB1 
 KR-S-026S was selected by flow cytometry because it diminished the 
surface level of HSPB1 most dramatically compared to other GPM1 derivatives. 
We confirmed the effect of KR-S-026S on HSPB1 surface level. 
 In order to confirm that KR-S-026S is effective for HSPB1 only on the 
cell membrane instead of whole HSPB1 level in the cell, we fractionated RAW 
264.7 cell into whole cell lysate, cytosol, and plasma membrane. We confirmed 
that the whole level of HSPB1 was not reduced under the treatment of GPM1 or 
KR-S-026S. Additionally, each samples were equally quantified as seen by equal 




 ATPase (plasma membrane 
marker) (Fig 2A). Moreover, HSPB1 in the cytosol portion remained unchanged 
under the treatment of GPM1 or KR-S-026S. However, treatment of GPM1 or KR-
S-026S decreased level of HSPB1 in the plasma membrane portion. And KR-S-
026S dramatically reduced level of HSPB1 in the plasma membrane (Fig 2A). 
These data show that the treatment of GPM1 or KR-S-026S do not affect the whole 
HSPB1 level, but reduce level of HSPB1 only in the plasma membrane fraction. 
 Furthermore, chemical effect on surface HSPB1 level was visualized 
under fluorescence microscopy. Permeabilization step was omitted to visualize 
HSPB1 only on the cell membrane. About eight hundred RAW 264.7 cells were 
counted in five different areas and calculated for the mean intensity. With the 
background value being subtracted, GPM1 decreased 60% and KR-S-026S reduced 
90% surface HSPB1 intensity (Fig 2B). Taken together, KR-S-026S showed 




Chemical properties of KR-S-026S in chemical stability, permeability, and its 
effect on cell proliferation 
 After selection of KR-S-026S as the most promising compound, chemical 
properties of KR-S-026S were examined. In order to investigate the toxicity of the 
compound, RAW 264.7 cells were treated with DMSO, KR-S-026S, and 
doxorubicin. Doxorubicin was used as a negative control because it hinders cell 
proliferation by inhibiting progress of DNA replication. And KR-S-026S was 
added with different concentrations: 2.5, 5, 10, 20 μM. Cell proliferation was not 
affected by the treatment of DMSO or KR-S-026S; however, treatment of 
doxorubicin diminished cell proliferation over time (Fig 3A). There was no 
significant difference in different concentrations of KR-S-026S. This data implies 
that KR-S-026S is not toxic on the proliferation of RAW 264.7 cell.  
 Next, human and rat liver microsomal stabilities of GPM1 and KR-S-
026S were examined in order to compare the chemical stabilities of GPM1 and 
KR-S-026S. Chemicals were incubated with human or rat liver microsome for 30 
min, and amount of chemicals remaining were measured. In human liver 
microsome, more than 99% of KR-S-026S was remained whereas only 0.1% of 
GPM1 was remained. In rat liver microsome, more than 89% of KR-S-026S was 
remained but GPM1 was not detected after 30 min (Fig 3B). This data implies that 
stability of KR-S-026S was dramatically enhanced compared to GPM1. Microsome 
stability indicates metabolic biotransformation of a drug. Low microsome stability 
indicates short half-life and thereby low response to the agent. In contrast, KR-S-




 We then investigated cell permeability of KR-S-026S on MDCK cell to 
see its effectiveness in absorption level. Metoprolol was used as a positive control 
that it has high absorption level whereas atenolol was used as a negative control 
because it has low absorption level. 50 μM of KR-S-026S was treated and showed 
exceptionally high cell permeability with papp value of 24 x 10
-6
 cm/sec. Papp 
value of metroprolol and atenolol were 13 x 10
-6
 cm/sec and 0.2 x 10
-6
 cm/sec, 
respectively (Fig 3C).  This data indicates that KR-S-026S has high cell 
permeability on MDCK cell and thereby high absorption level.  
 
Effect of KR-S-026S on autoimmune disease in NZB/W F1 mice 
 We prepared NZB/W F1 mice, chronically expressing autoimmune 
disease, to examine the chemical effect on autoimmune disease. NZB/W F1 mice 
starts to develop autoimmune disease typically from the age of 18 weeks. 
Therefore, in order to assume and assure that all groups of mouse are induced with 
severe autoimmune disease, we started daily chemical treatment at the age of 24 
weeks for 2 months. NZB/W F1 mouse were divided into 3 groups: vehicle, GPM1 
treated group, and KR-S-026S treated group.  
 High level of proteinuria is an indication of an autoimmune disease that 
we measured proteinuria level to examine the severity of autoimmune disease in 
each groups. Because NZB/W F1 mouse model develops severe autoimmune 
disease, proteinuria level was increased in every group after treating chemicals for 
8 weeks. However, proteinuria level of KR-S-026S treated group did not increase 




and 71% for vehicle and GPM1 treated group respectively whereas it increased 
only 55% for KR-S-026S treated group (Fig 4A). Therefore, KR-S-026S alleviated 
one of the symptoms of autoimmune disease effectively.  
 Additionally, each group contained 9 mouse at the beginning of the 
chemical treatment. However, 2 mouse in vehicle group died in third and fourth 
week respectively presumably due to severe autoimmune disease whereas no 
mouse were died in GPM1 or KR-S-026S treated groups (Fig 4B). Therefore, we 
can conclude that GPM1 and KR-S-026S have beneficial effect on survival of 
autoimmune disease induced NZB/W F1 mouse model.  
 This study highlights the critical role of cell surface expressed HSPB1 and 
suggests that HSPB1 can be a therapeutic target for autoimmune disease. Moreover, 
these results demonstrate that the treatment of KR-S-026S ameliorated symptoms 
of autoimmune disease in NZB/W F1 model by decreasing the cell surface level of 






































Figure 1. Screening strategy and selection of the most effective GPM1 
derivative. 
(A) Screening flow to identify the lead compound which functionally 
mimics AIMP1. Primary selection was performed to select the 
compound that can inhibit HSPB1 surface translocation and directly 
bind to HSPB1 with no in vivo toxicity. GPM1 was selected from the 
primary selection and GPM1 derivatives were synthesized for the 
secondary selection. Secondary selection was performed to select the 
compound with enhanced effect in reducing cell surface HSPB1 level 
and enhanced chemical property; and as a result, KR-S-026S was 
selected as a final compound. 
(B) GPM1 derivatives share similar chemical structure that they all have 
4,6-dimethoxypyrimidine. 
(C) RAW 264.7 cells were treated with DMSO or 10 μM of indicated 
chemicals dissolved in DMSO for 24 h. HSPB1 expressed on the cell 
surface was stained with HSPB1 antibody and FITC-conjugated anti-
rabbit secondary antibody. Y-axis represents amount of HSPB1 



































Figure 2. Dramatically decreased surface levels of HSPB1 upon KR-S-026S 
treatment. 
(A) RAW 264.7 cells treated with indicated compounds were fractionated 
into cytosol and plasma membrane. Proteins from each segment were 









 ATpase and α-
tubulin were used as markers for plasma membrane and cytosol, 
respectively. 
(B) DMSO, 10uM of GPM1 and KR-S-026S were treated in RAW 264.7 
cell for 24 h. Cells were fixed with PFA and permeabilization step was 
omitted in order to analyze HSPB1 only on the cell surface. Cell 
surface HSPB1 was detected using anti-HSPB1 antibody with 
secondary FITC-conjugated antibody and the green signal represents 
HSPB1. About eight hundred RAW 264.7 cells in five different area 





































Figure 3. Chemical properties of KR-S-026S in stability, permeability, and cell 
proliferation level. 
(A) RAW 264.7 cells were treated with KR-S-026S with indicated 
concentration and the real time cell proliferation was measured by 
Incucyte. Doxorubicin (1.25 μM) was used as a negative control. 
(B) Chemical stability of KR-S-026S analyzed with human and rat liver 
microsomes was compared with GPM1. Human or rat liver microsome 
(0.5 mg/ml) was incubated with 10 μM of compounds for 30 min. 
Numerical value indicates amount of chemicals remaining after 30 min 
incubation.  
(C) Permeability of KR-S-026S was measured by permeability assay with 
MDCK cell. Metoprolol and atenolol were used as positive and 
negative control, respectively. All chemicals were treated in the 
concentration of 50 μM and incubated for 4 h at 25
o
C. Y-axis indicates 


























Figure 4. In vivo effect of KR-S-026S on autoimmune disease phenotypes in 
NZB/W F1 mouse model. 
(A) Protein concentrations (mg/dL) in the urines, measured from vehicle 
(n=7), GPM1 (n=9), and KR-S-026S (n=9) treated groups for 8 weeks 
and proteinuria level from each samples was analyzed by Accute 
TBA-40FR. 
(B) Number of survived mice in vehicle, GPM1 treated and KR-S-026S 
treated groups. In the vehicle group, one mouse died at the third week 
















Figure 5. A schematic model representing function of KR-S-026S on 
autoimmune disease environment. 
(A) In normal environment, HSPB1 circulates between ER and golgi by 
retrograde transport supported by AIMP1. 
(B) In autoimmune disease environment, HSPB1 no longer retrograde 
back to the ER and translocates to the plasma membrane instead. 
Surface translocation of HSPB1 induces autoimmune disease which is 
relieved by treatment of KR-S-026S supporting retrograde transport of 



















Autoimmune disease is characterized by production of autoantibodies attacking 
normal tissues. Clinically, corticosteroids are commonly used for treatment of 
autoimmune disease. Corticosteroids relieve the symptoms by suppressing 
production of immune cells and inflammation (23). They were introduced to 
relieve symptoms for autoimmune disease and decreased mortality rate of 
autoimmune disease (24). However, long term usage of corticosteroid is associated 
with severe side effects such as infection, hypertension, hyperglycema, avascular 
necrosis, osteoporosis, cataracts, glaucoma, and myopathy (23). Therefore, 
developing target or mechanism based therapy for autoimmune disease has 
significant implication.  
HSP members, HSP60, HSP70, HSP90 families are known to be linked with 
immune stimulation (25, 26). Studies have found that HSP90 families are 
overexpressed in patients with autoimmune disease (27). One of the members of 
HSP90 family, HSP90B1 or gp96 is highly associated with autoimmune disease 
that its cell surface localization induces aberrant activation of immune cells and 
consequently induces autoimmune disease (21, 22, 28). Previously, we have found 
that AIMP1 supports retrograde transport of HSPB1 to the ER; we investigated 
compound that is able to substitute for the role of AIMP1, supporting retrograde 
transport of HSPB1 to the ER 
We have previously identified GPM1 as a lead compound. However, due to 
poor chemical stability, we composed GPM1 derivatives with different chemical 




decreasing cell surface level of HSPB1 by flow cytometry (Fig 1C). For further 
verification of effectiveness of KR-S-026S, we evaluated HSPB1 in cell surface 
level with immunofluorescence which showed remarkable decrease in HSPB1 at 
the plasma membrane of RAW 264.7 cells (Fig 2B). Furthermore, cytosol and 
plasma membrane of RAW 264.7 cells were fractionated and HSPB1 in plasma 
membrane decreased dramatically (Fig 2A).  
Biotransformation is the chemical modification of biological system upon 
foreign substrate. Many drugs fail to sustain in the body system or lose their 
capability in biological system. For instance, half-life of a drug can be affected 
depending on its metabolic biotransformation (29). In order to confirm the 
chemical stability of KR-S-026S, we checked microsomal stability, permeability, 
and cell viability upon treatment of KR-S-026S. Microsomal stability of GPM1 
was poor that it could not stay in the body system more than 30 minutes, indicating 
less effectiveness as a compound. However, KR-S-026S showed high microsomal 
stability both in human and rat, meaning that it is able to stay in the human or rat 
body and present its effectiveness to the target (Fig 3B). Furthermore, KR-S-026S 
had no adverse effect on cell viability, demonstrating that it has little toxic effect 
on RAW 264.7 cell (Fig 3A). KR-S-026S also had high level of permeability on 
MDCK cell, epithelial cell (Fig 3C). These data imply that chemical properties of 
KR-S-026S in absorption and stability were favorable; and it had little effect on 
cell proliferation.  
Previous in vivo data showed effect of GPM1 on HSPB1tm transgenic mice in 




GPM1, mouse had reduced proteinuria, serum levels of nuclear antigen-specific, 
and double stranded DNA-specific autoantibodies. We used NZB/W F1 mouse 
which develop autoimmune disease from the age of 18 weeks (30). In order for 
mouse model to develop severe autoimmune disease, we started the chemical 
treatment from the age of 24 weeks for 2 months. NZB/W F1 mouse model 
developed high level of proteinuria, which is a hallmark of severe autoimmune 
disease (31). And as chemicals were treated, level of proteinuria of KR-S-026S 
treated group did not increase as much as control group or GPM1 treated group 
(Fig 4A). Moreover, two mice died in DMSO treated group presumably due to 
severe autoimmune disease whereas no mouse died in the other groups, indicating 
that GPM1 and KR-S-026S have beneficial effect in survival of NZB/W F1 mouse 
model (Fig 4B).  
We selected KR-S-026S from GPM1 derivatives due to its ability to reduce cell 
surface level of HSPB1 with enhanced chemical property. We showed that 
treatment of KR-S-026S ameliorated symptoms of autoimmune disease and 
survival rate in NZB/W F1 model. Therefore, we can conclude that KR-S-026S is a 
promising therapeutic compound in autoimmune disease by controlling 
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HSP90B1 세포표면 이동의 화학적 억제와  




분자의학 및 바이오제약학과 의약생명과학전공 
임종하 
 
 자기 면역 질환은 자신의 면역세포에 의해 공격받는 질병으로 
알려있다. HSP90B1 혹은 gp96은 소포체와 골지 사이를 순환하는 샤프론 
단백질이다. 하지만 자기 면역 질환의 모델에서 HSPB1은 소포체와 골지 
사이를 순환하지 않고 세포막으로 이동하여 면역세포를 활성화 시키는 
것으로 연구가 되어있다. 세포막에 존재하는 HSPB1은 수지상 세포를 
과도하게 활성화 시키고 그러한 수지상 세포들은 T 세포와 B 세포의 
활성을 돕게 된다. 마지막으로 T와 B 세포들은 자기 조직을 공격하게 
되어 자기 면역 질환을 유도하게 된다. 따라서 HSPB1의 세포막 이동은 
자기 면역 질환에서 중요한 역할을 하며 이러한 질병에서 세포막에 
위치하는 HSPB1의 양이 증가하는 것으로 알려져 있어 자기 면역 질환의 
타깃으로 고려될 수 있다. 그리고 HSPB1의 세포막 이동을 막는 역할을 
한다는 단백질로써 AIMP1이라는 단백질이 알려져 있다. 정상적인 
상태에서 AIMP1은 HSPB1과 결합하여 소포체에 머무르도록 도와주는 




분리되어 있다. 그러기 때문에 AIMP1의 역할은 자기 면역 질환에서 
HSPB1의 세포막 이동을 조절함으로써 매우 중요한 역할을 한다.  
 따라서 우리는 AIMP1을 기능적으로 모방하는 화합물을 
스크리닝 하였다. 화합물들 중 HSPB1의 세포막 레벨을 가장 많이 
낮추고 독성이 없는 화합물로써 GPM1이 선정이 되었다. 자기 면역 
질환이 유도된 쥐를 이용한 생체 내 실험에서 GPM1 처리 군에서 
질병이 완화된 것을 확인할 수 있었다. 하지만 화합물의 안정성에 
있어서 GPM1은 매우 불안정하였다. 불안정한 화합물은 채 내에서 
약효가 나타나기 전에 분해되어 버리기 때문에 화합물의 발달 과정에 
있어서 매우 중요한 단계이다. 따라서 우리는 GPM1과 유사한 구조를 
갖은 파생물들을 합성하였다. 그리고 파생물들 중 가장 효과적으로 
HSPB1의 세포막 레벨을 감소 시키는 화합물을 선정하여 KR-S-026S라는 
화합물이 선정되었다. 이 화합물은 세포에서 HSPB1의 세포막 레벨을 
감소시키는 것 뿐만 아니라 자기 면역 질환이 유도된 쥐에서, GPM1 
보다 더욱 극적인 질환 개선 효과를 보였다. 뿐만 아니라, KR-S-026S는 
GPM1과는 다르게 높은 안정성을 보였고 삼투성과 독성효과를 보았을 
때에도 매우 양호한 화합적 요소를 갖추고 있다. 따라서 AIMP1의 
역할을 모방하며 HSPB1의 세포막 이동을 막는 KR-S-026S는 자기 면역 
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